title: Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke.
abstract: Filgratism (granulocyte colony stimulating factor, G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) have replaced bone marrow (BM) as a preferred source of autologous stem cells, in light of the faster hematologic recovery and lesser supportive care requirement exhibited by PBPC transplants. Other hematopoietic stem cells, like the human umbilical cord blood-derived stem cells (hUCBs), and nonhematopoietic stem cells have been shown to improve motor function in rodent models of injury and degenerative disease. In the present study we transplanted either G-CSF-mobilized PBPCs or hUCBs in rats 24 h after permanent middle cerebral artery occlusion (MCAO), and assessed their behavioral abnormalities in spontaneous activity and spontaneous motor asymmetry. In both transplanted groups of rats we observed a significant reduction of the stroke-induced hyperactivity compared with nontransplanted, stroked animals. In addition, transplantation of G-CSF PBPC and hUCB cells prevented the development of extensive motor asymmetry. Our findings raise the possibility that PBPCs could provide a novel transplantation therapy to treat stroke.
authors.affiliation: Center of Excellence for Aging & Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd, Tampa, FL 33612, USA. awilling@hsc.usf.edu
authors.forename: Alison E
authors.initials: AE
authors.lastname: Willing
authors.forename: Martina
authors.initials: M
authors.lastname: Vendrame
authors.forename: Jennifer
authors.initials: J
authors.lastname: Mallery
authors.forename: C Jordan
authors.initials: CJ
authors.lastname: Cassady
authors.forename: Cyndy D
authors.initials: CD
authors.lastname: Davis
authors.forename: Juan
authors.initials: J
authors.lastname: Sanchez-Ramos
authors.forename: Paul R
authors.initials: PR
authors.lastname: Sanberg
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D006948:Hyperkinesis / Q000209:etiology / Q000628:therapy; D020244:Infarction, Middle Cerebral Artery / Q000628:therapy; D007275:Injections, Intravenous; D009069:Movement Disorders / Q000209:etiology / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D020521:Stroke / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D016298:Hematopoietic Cell Growth Factors; D016179:Granulocyte Colony-Stimulating Factor